How likely is it that we will need a hantavirus vaccine? Epidemiologist Raywat Deonandan from the University of Ottawa weighs in on this question and others related to Canada's pandemic preparedness. In a recent interview, Deonandan noted that Canada is in a better position than it was six years ago but still lacks key elements to become a vaccine hub.
Canada's Vaccine Hub Aspirations
Deonandan explained that while Canada has made strides in vaccine research and development, it has not yet achieved the capacity to produce vaccines domestically at scale. This gap leaves the country vulnerable to future pandemics and emerging infectious diseases like hantavirus.
Hantavirus Risk and Vaccine Development
Hantavirus, a rodent-borne disease, can cause severe respiratory illness in humans. Outbreaks are rare but can be deadly. Deonandan emphasized that the likelihood of needing a hantavirus vaccine depends on the frequency of outbreaks and the virus's potential to spread. Currently, no approved hantavirus vaccine exists, but research is ongoing.
Lessons from COVID-19
The COVID-19 pandemic highlighted the importance of domestic vaccine production. Canada relied heavily on foreign manufacturers, leading to delays in vaccine rollout. Deonandan stressed that becoming a vaccine hub would require investment in manufacturing infrastructure, skilled workforce, and regulatory agility.
Public Health Preparedness
Beyond vaccines, Deonandan called for strengthened public health surveillance and rapid response systems. He noted that Canada's geographic isolation and strong healthcare system provide advantages, but political will and sustained funding are essential to close gaps.
While a hantavirus vaccine may not be imminent, the discussion underscores the need for proactive measures to protect Canadians from future health threats. Deonandan's insights serve as a reminder that pandemic preparedness requires continuous effort and investment.
